Uses
INDICATION Cystografin is indicated for retrograde cystourethrography.
Source: US FDA prescribing information
Molecule
Diatrizoate is a radiographic contrast agent indicated for retrograde cystourethrography. It is available as oral solution, injection and oral liquid for rectal and intravenous use. MedsAcross supplies Diatrizoate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
INDICATION Cystografin is indicated for retrograde cystourethrography.
Source: US FDA prescribing information
Preparation of the patient: Appropriate preparation is desirable for optimal results. A laxative the night before the examination and a low residue diet the day before the procedure are recommended. Dosage: The dose for retrograde use in cystography and voiding cystourethrography ranges from 25 to 300 mL depending on the age of the patient and the degree of bladder irritability, amounts greater than 300 mL may be used if the bladder capacity allows. Best results are obtained when the bladder is filled with the contrast agent. If desired, the preparation may be diluted with sterile water or sterile saline as indicated in the table below. Administration: After sterile catheterization, the bladder should be filled to capacity with Cystografin using a suitable sterile administration set. Care should be taken to avoid using excessive pressure.
Source: US FDA prescribing information
This preparation is contraindicated in patients with a hypersensitivity to salts of diatrizoic acid.
Source: US FDA prescribing information
Severe sensitivity reactions are more likely to occur in patients with a personal or family history of bronchial asthma, significant allergies, or previous reactions to contrast agents. A history of sensitivity to iodine per se or to other contrast agents is not an absolute contraindication to the use of diatrizoate meglumine, but calls for extreme caution in administration.
Source: US FDA prescribing information
Retrograde genitourinary procedures may cause such complications as hematuria, perforation of the urethra or bladder, introduction of infection into the genitourinary tract, and oliguria or anuria. If intravasation of this drug occurs, the reactions which may be associated with intravenous administration may possibly be encountered. Hypersensitivity or anaphylactoid reactions may occur. Severe reactions may be manifested by edema of the face and glottis, respiratory distress, convulsions or shock, such reactions may prove fatal unless promptly controlled by such emergency measures as maintenance of a clear airway and immediate use of oxygen and resuscitative drugs.
Source: US FDA prescribing information
Store at 20-25°C (68-77°F). Protect from light.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
6 presentations of Diatrizoate, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Diatrizoate 660 mg/100 mg per mL oral solutionOral, rectalGeneric name | — | US FDA | Available on request |
| Gastrografin 660 mg/100 mg per mL oral liquidOral, rectal | Bracco Diagnostics | US FDA | Available on request |
| Cystografin 30000 mg/100 mL injectionIntravenous | Bracco Diagnostics | US FDA | Available on request |
| Cystografin 90000 mg/300 mL injectionIntravenous | Bracco Diagnostics | US FDA | Available on request |
| Cystografin Dilute 54000 mg/300 mL injectionIntravesical | Bracco Diagnostics | US FDA | Available on request |
| MD Gastroview 600 mg/100 mg per mL oral solutionOral, rectal | Liebel-Flarsheim | US FDA | Available on request |
4 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 26 November 1954 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 6 presentations of Diatrizoate and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 4 brand names for Diatrizoate, including Cystografin, Cystografin Dilute, Gastrografin, MD Gastroview.
Yes. The US FDA first approved Diatrizoate on 26 November 1954, according to Drugs@FDA.
No listed presentation of Diatrizoate is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Diatrizoate is classified under ATC code V08AA01 (Diatrizoate).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.